Best practices for counselling on long-acting injectable antipsychotics

Long-acting injectable antipsychotics can make maintenance treatment more predictable for people with schizophrenia, bipolar disorder, or another severe mental health condition. A depot injection may reduce missed doses and help prevent relapse, yet it does not replace recovery support, physical health monitoring, or review of the person’s goals. For community pharmacists, the medicine is part of a network involving prescribers, mental health nurses, general practice, hospitals, and family or chosen supporters.

Best practice for dispensing and counselling on long-acting injectable antipsychotics begins with the product in front of you, not the calendar alone. Risperidone, paliperidone, olanzapine, zuclopenthixol and fluphenazine decanoate have different release durations, storage conditions, dosing schedules and requirements for oral overlap. Dose and interval belong to the treating clinician; a pharmacy should never convert one depot formulation, strength or schedule into another without authorised clinical direction.

An LAI prescription also represents a scheduled encounter with a person who may be anxious, stigmatised, unwell, or receiving care from several services. A technically correct handover can fail if the patient does not know why the dose is needed, what will happen, or where to go next. Privacy, trauma-informed care, supported decision-making and accessible communication are therefore clinical controls, not optional courtesies.

Consistency matters when a person moves between an acute ward, an outpatient clinic, a community pharmacy and a GP surgery. Local arrangements differ across Australia: some depot doses are administered in hospital clinics, while others are supplied to accredited pharmacies for nurse or authorised practitioner administration. PBS subsidy, specialist-stream authority, product availability and after-hours coverage can all affect the route. Good workflow design makes those differences visible without treating any patient as a routine refill.

Confirm indication, capacity, and treatment goals

Before stock is selected, review the prescription and the person’s medicines. Confirm the indication, target symptoms, previous response, allergies, current oral or injectable antipsychotics, relevant cardiovascular, renal, hepatic and metabolic conditions, and recent adverse effects. Check that the order names the active ingredient, formulation, dose, route and interval, and is valid under applicable state or territory requirements for Schedule 4 poisons. Do not assume that a prescription for one paliperidone product permits substitution with another.

Ask how the person is experiencing treatment and whether their preferences have been discussed. Capacity is decision-specific and may fluctuate with psychosis, sedation or mood disturbance. If a person refuses an injection, explore what happened, involve the treating team, arrange an interpreter or communication support, and seek a capacity assessment where appropriate. Involuntary administration requires a valid legal pathway and clearly documented authority; a pharmacy record alone is not sufficient.

Establish a clinical baseline and an agreed review date. Many depot medicines are started only after oral tolerability has been shown; some products offer specific initiation or oral-supplement instructions. Follow the Australian Product Information and the prescriber’s plan rather than generalising from another medicine. The value of pharmacists in explaining access to treatment is also illustrated in PrEP and PEP education, where trusted community engagement supports informed uptake and continuity.

Standardise dispensing, storage, and administration

Treat every product as distinct from every other. Check the brand, formulation, strength, approved injection site, reconstitution method, supplied diluent, storage range and observation requirements against the current Product Information. Some packs require refrigeration, while others must remain at controlled room temperature. Record temperature on receipt and before preparation, quarantine questionable stock and contact the supplier or state pharmacy department; visual inspection alone cannot establish that temperature-sensitive medicine is safe.

Preparation and administration should follow a written workflow and occur only by appropriately trained, authorised staff with current credentials, suitable equipment and emergency access. Follow the manufacturer’s sequence for reconstitution, use the specified diluent, and never mix residual medicine from a multidose vial. Observe for the period stated in the Product Information or local policy. Document the batch, expiry, site, person who administered the dose, observation and any reaction, then update the next-due date and patient-held record.

Systems should also cover recalls, short supplies, dose changes and communication after hospital discharge. A clear referral note prevents a patient from carrying an administration instruction between services that use different terminology. Useful governance thinking on building capable pharmacy teams is available in pharmacy leadership perspectives. Locally, a metropolitan pharmacy in Melbourne, Sydney or Brisbane may sit beside several hospital catchments, so named contacts and escalation routes are more useful than a generic phone number.

Use a clear, consent-based counselling conversation

Use plain language to explain why the medicine is being offered, what a depot formulation does, and what it cannot do. Describe the visit step by step, including privacy, injection discomfort, the likelihood of tenderness or bruising, and the observation period. Discuss expected benefits, uncertainty, common effects and alternatives in line with the clinician’s plan. Cover sedation, appetite or weight change, akathisia, stiffness, tremor and sexual effects as relevant, while distinguishing common effects from urgent reactions. Ask the person which outcomes matter to them, such as fewer admissions, greater stability at home, or easier engagement with work and family.

Provide practical information in writing and use teach-back to check understanding rather than asking only whether questions remain. Confirm which oral medicines continue, why an oral overlap may be required, and that doses should not be stopped, delayed or changed without advice. Give the next-due date, clinic address, opening hours, after-hours plan and a direct contact pathway. Explain what to do if an appointment is missed, symptoms worsen, or a concerning reaction occurs. An emergency card can help the person and a new clinician identify the product, dose and last injection date.

Respect confidentiality when involving family. Ask permission, distinguish support from substitute decision-making, and record who may receive information. Trauma-informed care, Auslan interpreters, translated plain-language materials and Aboriginal cultural support may be needed. Some people describe injectable treatment as coercion because they feel unheard; taking time to explain choice, allow time for discussion and acknowledge concerns can preserve both safety and trust.

Monitor physical health, psychiatric risk, and treatment response

Depot medication requires the same disciplined physical health surveillance as oral antipsychotics, with attention to individual risk and product effects. Agree review intervals for weight, body mass index, waist circumference, blood pressure, fasting glucose or HbA1c, lipids, and movement symptoms. Consider prolactin testing when indicated, ECG where clinically appropriate, and assessment of sedation, cognition, sexual function and falls. Apply product-specific evidence in context: olanzapine is associated with greater weight and metabolic effects, while prolactin elevation is particularly relevant with risperidone and paliperidone.

Record trends and escalate meaningful change to the prescriber instead of waiting for the next depot appointment. Recognise and document acute warning signs: marked sedation, sudden confusion, fever with severe rigidity or confusion, fainting, new or worsening movement disorder, chest symptoms, or severe allergic reaction. Post-injection delirium or sedation can occur, especially soon after a dose or when other sedating medicines are used.

Emergency help is appropriate for anaphylaxis, collapse, breathing difficulty or other time-critical symptoms; in Australia, call 000. For urgent but non-life-threatening concerns, use the treating service’s after-hours pathway rather than waiting for a routine review. Review adherence without assuming that regular attendance proves engagement. Ask about transport, cost, pain, stigma, waiting times, caring responsibilities, and whether the person wants a different approved administration setting. Do not recommend abrupt discontinuation because withdrawal and relapse risk can be substantial; contact the treating team promptly.

Coordinate transitions, access, and continuity

Transitions create the greatest risk of accidental gaps. After an emergency department presentation or inpatient discharge, the team should document the last dose, next eligible date, oral transition plan, prescriber, dispensing route, and named clinician responsible for follow-up. Send a concise handover to the community provider and ask the patient to carry their medication record. Reconcile the first community appointment before discharge when discharge is on a weekend or public holiday.

Make the supply pathway explicit. Some LAI antipsychotics are PBS-listed under specialist arrangements, and a script may require authority, specified brands or repeats from an authorised prescriber. Confirm claims, co-payment support, stock and the exact formulation before the person leaves the service. A medicine may be subsidised through the PBS while administration is provided through a public hospital, community clinic, GP or accredited pharmacy; Medicare funding for administration varies by provider and service, so explain who to contact for each part rather than directing every query to the dispensing pharmacy.

Design for the realities of Aboriginal and Torres Strait Islander clients and regional communities without prescribing one model for all. Partner with Aboriginal health practitioners, Aboriginal Medical Services and Aboriginal Community Controlled Health Organisations where appropriate, and allow family or community representatives to be involved according to the person’s wishes. In remote areas, travel and limited cold-chain infrastructure may determine where a dose can safely be given. Continuing professional material on the pharmacist’s role in education and access can be found in pharmacist education resources, but local relationships and clear service agreements remain essential.

Implement one organisation-wide LAI pathway with a single medication record, current product-specific information, defined ownership for reconciliation, and escalation after missed doses or reactions. Give every patient an understandable schedule, written after-hours instructions, and the contact details of a clinician who can act. Audit completion of physical health monitoring, PBS documentation, consent discussions and transitions, then use the findings to improve the service rather than blaming individuals for system failures.

The next LAI prescription should trigger a coordinated episode of care, not an isolated dispensing transaction. By combining precise product handling, consent-based counselling, physical and psychiatric monitoring, and reliable communication across Australia’s pharmacy, hospital, primary care and community networks, pharmacists can help people receive depot treatment safely, consistently and with dignity. Make that standard the default in every pharmacy and service that supplies or administers these medicines.